Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Wraps Up Enrollment in RSV Drug Trial


Alnylam Pharmaceuticals announced this week that it has completed enrollment in a phase IIb study of its investigational respiratory syncytial virus therapy ALN-RSV01.

The trial is a multi-center, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients, according to the company. It is being conducted at lung-transplant centers in six countries. As previously disclosed, data are expected to be reported mid-2012 (GSN 11/3/2011).

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.